|
|
 |
 |
|
 |
 |
| In the next year, U.S. regulators may approve gene therapies – to treat sickle cell disease. But gene therapies come with a high price tag — and it’s estimated that roughly 40% of sickle cell patients are covered by #Medicaid. buff.ly/35UOqlP |
|
| 3/14/22, 5:25 PM |
|
|
|
Published by Joseph Thornton MD
Teacher, Clinical Supervisor
Clinical Associate Professor, Psychiatry
University of Florida
Affiliation is for identification only. All content and opinions are my own.
View more posts
Gator Psychiatry 